EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal Viruses

Álex Gómez iD, Ramsés Reina iD

Viruses · 2025-05-21 · 17 (5) · 737

DOI: 10.3390/v17050737 ↗

At a glance

Übersichtsarbeit in Viruses, published online on 2025-05-21. Written by Álex Gómez and 1 co-authors. Institution: Departamento de Patología Animal, Universidad de Zaragoza, 177 Calle de Miguel Sevet, 50013 Zaragoza, Spain. Major MEDLINE topics: Sendai virus, Viral Vaccines, Genetic Vectors, Virus Diseases. Cited 6 times so far (Crossref); 129 references. The full text is freely available (open access, CC BY 4.0). Funded by: Gobierno de Navarra.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Vaccination plays a pivotal role in the control and prevention of animal infectious diseases. However, no efficient and safe universal vaccines are currently registered for major pathogens such as influenza A virus, foot-and-mouth disease virus (FMDV), simian immunodeficiency virus (SIV), and small ruminant lentiviruses (SRLV). Here, we review the development of Sendai virus (SeV) vectors as a promising vaccine platform for animal diseases. Recombinant SeV vectors (rSeVv) possess several key features that make them highly suitable for developing vaccination strategies: (1) SeV has exclusively cytoplasmic replication cycle, therefore incapable of transforming host cells by integrating into the cellular genome, (2) rSeVv can accommodate large foreign gene/s inserts (~5 kb) with strong but adjustable transgene expression, (3) can be propagated to high titers in both embryonated chicken eggs and mammalian cell lines, (4) exhibits potent infectivity across a broad range of mammalian cells from different animals species, (5) undergo transient replication in the upper and lower respiratory tracts of non-natural hosts, (6) has not been associated with disease in pigs, non-humans primates, and small ruminants, ensuring a favorable safety profile, and (7) induce a robust innate and cellular immune responses. Preclinical and clinical studies using rSeVv-based vaccines against influenza A virus, FMDV, SIV, and SRLV have yielded promising results. Therefore, this review highlights the potential of rSeVv-based vaccine platforms as a valuable strategy for combating animal viruses.

Subjects

MeSH terms (MEDLINE)

Sendai virusViral VaccinesGenetic VectorsVirus DiseasesAnimal DiseasesAnimalsVaccines, SyntheticHumans

Author keywords

Sendai virus vectoranimalsimmune responsevaccine

Substances

Viral VaccinesVaccines, Synthetic

Authors and institutions

  • Departamento de Patología Animal, Universidad de Zaragoza, 177 Calle de Miguel Sevet, 50013 Zaragoza, Spain.
  • Instituto Agroalimentario de Aragón-IA2, Universidad de Zaragoza, 177 Calle de Miguel Sevet, 50013 Zaragoza, Spain.
  • Instituto de Agrobiotecnología (CSIC-Gobierno de Navarra), 123 Avenida Pamplona, 31192 Mutilva, Spain.

ORCID profiles: Álex Gómez, Ramsés Reina

Funding

  • Gobierno de Navarra

Cite

APA

Gómez, Á., & Reina, R. (2025). Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal Viruses. Viruses, 17(5), 737. https://doi.org/10.3390/v17050737

Vancouver

Gómez Á, Reina R. Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal Viruses. Viruses. 2025;17(5):737. doi:10.3390/v17050737

BibTeX
@article{Gmez2025,
  author = {Gómez, Álex and Reina, Ramsés},
  title = {Recombinant Sendai Virus Vectors as Novel Vaccine Candidates Against Animal Viruses},
  journal = {Viruses},
  year = {2025},
  volume = {17},
  number = {5},
  pages = {737},
  doi = {10.3390/v17050737}
}
Start for free →